Michael D. Miller

发表

Structures of HIV-1 RT–DNA complexes before and after incorporation of the anti-AIDS drug tenofovir

Roger A. Jones, A. D. Clark, G. Wang, 2004, Nature Structural &Molecular Biology.

Low pH Is Required for Avian Sarcoma and Leukosis Virus Env-Dependent Viral Penetration into the Cytosol and Not for Viral Uncoating

Michael D. Miller, J. Young, R. Barnard, 2004, Journal of Virology.

Isolated Lactobacillus chronic prosthetic knee infection.

Michael D. Miller, D. M. Bennett, Tatyana A Shekhel, 2014, Orthopedics.

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study

R. Schooley, G. Beall, Michael D. Miller, 2002, AIDS.

Abundant Drug-Resistant NS3 Mutants Detected by Deep Sequencing in Hepatitis C Virus-Infected Patients Undergoing NS3 Protease Inhibitor Monotherapy

Michael D. Miller, H. Mo, E. Svarovskaia, 2012, Journal of Clinical Microbiology.

Genotype- and Subtype-Independent Full-Genome Sequencing Assay for Hepatitis C Virus

Michael D. Miller, H. Mo, Simin Xu, 2015, Journal of Clinical Microbiology.

Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation

Bikram Chakraborty, Michael D. Miller, M. Quiñones-Mateu, 2005, Journal of Clinical Microbiology.

Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant.

Michael Rowley, Michael D. Miller, M. Rowley, 2006, Bioorganic & medicinal chemistry letters.

CD8+ Lymphocytes Control Viral Replication in SIVmac239-Infected Rhesus Macaques without Decreasing the Lifespan of Productively Infected Cells

Alan S. Perelson, Ruy M. Ribeiro, Nichole R. Klatt, 2010, PLoS pathogens.

Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.

Michael D. Miller, W. Schleif, R. Geleziunas, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.

Karen Holmes, Kathy Lyons, Joseph Kessler, 2004, Bioorganic & medicinal chemistry letters.

In Vitro Characterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor

Jason Burch, Yves Ducharme, Louis-Charles Campeau, 2013, Antimicrobial Agents and Chemotherapy.

Analysis of Low-Frequency Mutations Associated with Drug Resistance to Raltegravir before Antiretroviral Treatment

Feng Gao, Fangping Cai, Charles B. Hicks, 2010, Antimicrobial Agents and Chemotherapy.

Switching between raltegravir resistance pathways analyzed by deep sequencing

Richard L. Hodinka, Shane T. Jensen, Kyle Bittinger, 2011, AIDS.

Tenofovir alafenamide demonstrates broad cross‐genotype activity against wild‐type HBV clinical isolates and maintains susceptibility to drug‐resistant HBV isolates in vitro

Michael D. Miller, K. Kitrinos, Yang Liu, 2017, Antiviral research.

HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D

Michael D. Miller, K. Kitrinos, Yang Liu, 2014, Liver international : official journal of the International Association for the Study of the Liver.

In Vitro Drug Susceptibility Analysis of Hepatitis B Virus Clinical Quasispecies Populations

Michael D. Miller, Huiling Yang, W. Delaney, 2007, Journal of Clinical Microbiology.

A Critical Site in the Core of the CCR5 Chemokine Receptor Required for Binding and Infectivity of Human Immunodeficiency Virus Type 1*

M. Kavanaugh, Michael D. Miller, J. Lineberger, 1999, The Journal of Biological Chemistry.

Development and application of a fast, reproducible assay to measure HCV NS3 protease activity using Escherichia coli lysate.

Michael D. Miller, Xiaohong Liu, H. Mo, 2015, Journal of virological methods.

Evolution of tenofovir‐resistant HIV‐1 isolates exposed to tenofovir alafenamide dose escalation

Michael D. Miller, Renee R Ram, N. Margot, 2017, Antiviral research.

The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro

Michael D. Miller, C. Gibbs, E. Arnold, 2003, Journal of Virology.

HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications.

D. Hazuda, Michael D. Miller, M. Miller, 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Combinations of Adefovir with Nucleoside Analogs Produce Additive Antiviral Effects against Hepatitis B Virus In Vitro

Michael D. Miller, C. Gibbs, Huiling Yang, 2004, Antimicrobial Agents and Chemotherapy.

Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus

Michael D. Miller, Huiling Yang, W. Delaney, 2006, Antimicrobial Agents and Chemotherapy.

Target DNA capture by HIV-1 integration complexes

F. Bushman, Michael D. Miller, Y. Bor, 1995, Current Biology.

A potent and orally active HIV-1 integrase inhibitor.

Wei Xu, D. Hazuda, Michael D. Miller, 2007, Bioorganic & medicinal chemistry letters.

Inhibition of HIV-1 Ribonuclease H by a Novel Diketo Acid, 4-[5-(Benzoylamino)thien-2-yl]-2,4-dioxobutanoic Acid*

D. Hazuda, Michael D. Miller, J. Cole, 2003, The Journal of Biological Chemistry.

Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase Inhibitor

D. Hazuda, Michael D. Miller, M. Lai, 2009, Antimicrobial Agents and Chemotherapy.

Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure

K. Metzner, M. Kozal, R. Paredes, 2011 .

ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2–specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: Case report

Michael D. Miller, S. Mathai, C. Spak, 2021, American Journal of Transplantation.

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B

Michael D. Miller, P. Marcellin, K. Kitrinos, 2014, Hepatology.